GlaxoSmithKline's asthma drug mepolizumab achieved the primary goals of two late-stage trials. In one of them, patients with severe eosinophilic asthma who took the drug showed a significant decrease in frequency of exacerbations compared with those on placebo. In the other trial, mepolizumab users showed a greater decrease in oral corticosteroid dosage while maintaining asthma control compared with placebo users. The firm plans to submit the drug for regulatory review worldwide by the end of this year.
Published in Brief: